|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Dabigatran#Adult Indications and Dosage]] |
| {{Dabigatran}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARGATROBAN INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c9616c0-a299-4fd5-c8ae-79e6db453595 | publisher = | date = | accessdate = 31 January 2014 }}</ref>
| |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Direct thrombin (II) inhibitors]]
| |
| [[Category:Anticoagulants]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |